Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

US Department of Justice
Teva
US Army
Citi
Accenture
McKesson
AstraZeneca
Daiichi Sankyo
Chinese Patent Office
Covington

Generated: January 20, 2018

DrugPatentWatch Database Preview

Details for Patent: 4,585,790

« Back to Dashboard

Summary for Patent: 4,585,790
Title: Pharmaceutical compositions
Abstract:Aqueous formulations of raniditine have been found to have enhanced shelf life provided that they are formulated with a pH in the range 6.5--7.5. Suitable aqueous formulations include injections for intravenous and intramuscular administration, continuous infusions and oral preparations such as syrups.
Inventor(s): Padfield; John M. (Meldreth, GB2), Winterborn; Ian K. (Stevenage, GB2)
Assignee: Glaxo Group Limited (London, GB2)
Application Number:06/609,215
Patent Claim Types:
see list of patent claims
Use; Composition; Formulation; Dosage form; Process;

Drugs Protected by US Patent 4,585,790

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 4,585,790

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom83 13217May 13, 1983

International Patents Family Members for US Patent 4,585,790

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2792984 ➤ Subscribe
Australia 568647 ➤ Subscribe
Belgium 899635 ➤ Subscribe
Canada 1216240 ➤ Subscribe
Switzerland 662272 ➤ Subscribe
Czechoslovakia 9104036 ➤ Subscribe
Czech Republic 281598 ➤ Subscribe
Germany 3417606 ➤ Subscribe
Denmark 165663 ➤ Subscribe
Denmark 237884 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Novartis
UBS
Cipla
Queensland Health
Colorcon
Argus Health
Accenture
Federal Trade Commission
US Department of Justice

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot